Â鶹´«Ã½

    Advertisement
    Pharmafile12:20Novo Nordisk Health Pharma
    pharmaphorum08:50Novo Nordisk Health Pharma
    Quartz05:08Novo Nordisk FDA Pharma
    Quartz08:47Novo Nordisk FDA Pharma
    Journal of American Medical Associations11:50Mounjaro Health Tirzepatide
    Knowridge Science Report20:15Mounjaro Health Tirzepatide
    Health Magazine13:10Health
    Fox News05:28Health
    The Kansas City Star17:00Nikki Glaser
    UNILAD12:11Nikki Glaser
    Indian Express05:39Mounjaro Novo Nordisk India
    The Hindu Business Line12:23Mounjaro Novo Nordisk India
    Evening Standard04:41Jeremy Clarkson
    MailOnline15:03Jeremy Clarkson
    Financial Mail08:57Mounjaro Eli Lilly Novo Nordisk
    Wellbeing News04:06Mounjaro Tirzepatide
    JD Supra11:06Mounjaro Tirzepatide
    In the last 6 hours
    The Times of India21:22 3-Apr-25
    Irish Examiner21:04 3-Apr-25
    Yesterday
    MailOnline14:13 3-Apr-25
    LADbible11:50 3-Apr-25
    Delish10:55 3-Apr-25
    The West Australian07:16 3-Apr-25
    Fox News05:28 3-Apr-25
    9News00:25 3-Apr-25
    In the last 7 days
    MailOnline18:05 2-Apr-25
    HealthDay12:02 2-Apr-25
    Journal of American Medical Associations11:50 2-Apr-25
    Quartz11:13 2-Apr-25
    Echo News09:07 2-Apr-25
    Financial Mail08:57 2-Apr-25
    Next Avenue07:04 2-Apr-25
    HELLO!06:27 2-Apr-25
    Knowridge Science Report06:26 2-Apr-25
    Financial Mail04:22 2-Apr-25
    Quartz14:40 1-Apr-25
    People14:29 1-Apr-25
    The Hospitalist13:51 1-Apr-25
    The Hindu Business Line12:23 1-Apr-25
    Pharmafile12:20 1-Apr-25
    New Zealand Herald12:06 1-Apr-25
    MailOnline10:10 1-Apr-25
    LADbible05:08 1-Apr-25
    euronews03:07 1-Apr-25
    The Financial Express03:02 1-Apr-25
    MailOnline00:54 1-Apr-25
    MailOnline19:40 31-Mar-25
    TMZ.com19:00 31-Mar-25
    National World15:08 31-Mar-25
    FiercePharma11:44 31-Mar-25
    LADbible10:38 31-Mar-25
    Benzinga09:36 31-Mar-25
    pharmaphorum08:50 31-Mar-25
    Hindustan Times07:19 31-Mar-25
    LADbible07:03 31-Mar-25
    Yahoo! UK & Ireland06:40 31-Mar-25
    LADbible06:23 31-Mar-25
    Pharmaceutical Technology06:20 31-Mar-25
    Fortune06:06 31-Mar-25
    Evening Standard04:41 31-Mar-25
    The Independent03:18 31-Mar-25
    BANG Premier03:16 31-Mar-25
    LADbible02:48 31-Mar-25
    News-Medical.Net00:40 31-Mar-25
    MailOnline17:54 30-Mar-25
    Pharmacy Times17:25 30-Mar-25
    American Journal of Managed Care17:04 30-Mar-25
    MailOnline15:03 30-Mar-25
    American Journal of Managed Care13:40 30-Mar-25
    News-Medical.Net12:48 30-Mar-25
    Futurism12:41 30-Mar-25
    Pharmacy Times12:30 30-Mar-25
    The Mirror11:39 30-Mar-25
    PR Newswire (Press Release)10:02 30-Mar-25
    MailOnline09:27 30-Mar-25
    LADbible09:18 30-Mar-25
    Knowridge Science Report06:31 30-Mar-25
    Pharmacy Times01:07 30-Mar-25
    TCTMD17:24 29-Mar-25
    TCTMD15:01 29-Mar-25
    American Journal of Managed Care14:45 29-Mar-25
    Medpage Today14:39 29-Mar-25
    GlobeNewswire (Press Release)14:35 29-Mar-25
    Pharmacy Times11:24 29-Mar-25
    GlobeNewswire (Press Release)10:35 29-Mar-25
    Quartz08:47 29-Mar-25
    Knowridge Science Report20:15 28-Mar-25
    Health Magazine15:22 28-Mar-25
    Rock Hill Herald14:57 28-Mar-25
    Pharmacy Times14:12 28-Mar-25
    MailOnline11:19 28-Mar-25
    Yahoo! US08:47 28-Mar-25
    The Independent08:31 28-Mar-25
    Proactive Investors (US)08:29 28-Mar-25
    Plymouth Live06:33 28-Mar-25
    Quartz05:08 28-Mar-25
    The Motley Fool05:01 28-Mar-25
    Wellbeing News04:06 28-Mar-25
    In the last month
    FOX 11 Los Angeles22:19 27-Mar-25
    News-Medical.Net21:44 27-Mar-25
    Rock Hill Herald21:38 27-Mar-25
    Psychology Today20:24 27-Mar-25
    Rock Hill Herald17:44 27-Mar-25
    Quartz17:06 27-Mar-25
    Macon.com16:51 27-Mar-25
    BBC Science Focus15:22 27-Mar-25
    Women's Health14:40 27-Mar-25
    Storyful13:51 27-Mar-25
    Yahoo! UK & Ireland13:35 27-Mar-25
    EasternEye12:26 27-Mar-25
    UNILAD12:11 27-Mar-25
    American Journal of Managed Care11:33 27-Mar-25
    Medpage Today10:44 27-Mar-25
    Yahoo! UK & Ireland08:57 27-Mar-25
    Women's Health UK07:57 27-Mar-25
    Forbes07:50 27-Mar-25
    PsyPost18:07 26-Mar-25
    The Kansas City Star17:00 26-Mar-25
    Elle14:23 26-Mar-25
    Elle14:22 26-Mar-25
    Elle14:22 26-Mar-25
    New Scientist14:07 26-Mar-25
    Health Magazine13:10 26-Mar-25
    SELF Magazine09:11 26-Mar-25
    Forbes08:06 26-Mar-25
    GlobeNewswire (Press Release)07:32 26-Mar-25
    Bangkok Post02:58 26-Mar-25
    MailOnline16:36 25-Mar-25
    Just Jared (Weblog)15:40 25-Mar-25
    Footwear News15:31 25-Mar-25
    Pharmaceutical Technology13:27 25-Mar-25
    Zacks12:33 25-Mar-25
    view more headlines
    3 Apr 21:22

    About our Ozempic news

    Latest news on Ozempic, Wegovy, Rybelsus: semaglutide weight loss drugs making headlines for remarkable results, high demand, and celebrity use. Stay updated on these popular GLP-1 medications.

    Ozempic, Wegovy, and Rybelsus are brand names for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes treatment. These injectable and oral medications have gained significant attention for their impressive weight loss effects, with many users reporting rapid and substantial body weight reductions. As a result, demand for semaglutide drugs has skyrocketed, leading to shortages and waiting lists in some areas.

    Our semaglutide news feed brings you the latest updates on these groundbreaking weight loss drugs from reliable medical sources, pharmaceutical companies like Novo Nordisk, and real-world patient experiences. Stay informed about the efficacy, safety, and potential side effects of Ozempic, Wegovy, and Rybelsus, as well as ongoing clinical trials and research into their long-term effects and potential new applications.

    In addition to their medical aspects, semaglutide drugs have become a cultural phenomenon, with celebrities and influencers openly discussing their use of Ozempic and Wegovy for weight loss. Our feed covers these high-profile endorsements and the ensuing public discourse about the ethics and accessibility of these treatments. We also explore the societal implications of the growing popularity of semaglutide, including its impact on body image standards and the potential for exacerbating existing inequalities in healthcare access.

    As the demand for Ozempic, Wegovy, and Rybelsus continues to grow, our feed keeps you updated on supply chain issues, regulatory developments, and efforts by manufacturers to ramp up production and expand availability. We also cover debates surrounding insurance coverage for these weight loss drugs and the evolving policies of healthcare providers and payers.

    With obesity rates on the rise globally, the advent of effective weight loss medications like semaglutide has significant implications for public health and healthcare systems. Our semaglutide news feed delves into these broader contexts, exploring the potential of these drugs to combat the obesity epidemic and their role in comprehensive weight management strategies alongside lifestyle changes and other interventions.

    Stay at the forefront of the rapidly evolving landscape of semaglutide weight loss treatments with our continuously updated Ozempic, Wegovy, and Rybelsus news feed. Whether you're a healthcare professional, a person struggling with obesity, or simply interested in this groundbreaking development, our feed is your go-to source for comprehensive, nuanced coverage of these remarkable drugs.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.